These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18373975)

  • 1. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
    Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
    Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.
    Scholz F; Schulte A; Adamski F; Hundhausen C; Mittag J; Schwarz A; Kruse ML; Proksch E; Ludwig A
    J Invest Dermatol; 2007 Jun; 127(6):1444-55. PubMed ID: 17363916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.
    Gutwein P; Abdel-Bakky MS; Schramme A; Doberstein K; Kämpfer-Kolb N; Amann K; Hauser IA; Obermüller N; Bartel C; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
    Am J Pathol; 2009 Jun; 174(6):2061-72. PubMed ID: 19435795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.
    Gough PJ; Garton KJ; Wille PT; Rychlewski M; Dempsey PJ; Raines EW
    J Immunol; 2004 Mar; 172(6):3678-85. PubMed ID: 15004171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.
    Abel S; Hundhausen C; Mentlein R; Schulte A; Berkhout TA; Broadway N; Hartmann D; Sedlacek R; Dietrich S; Muetze B; Schuster B; Kallen KJ; Saftig P; Rose-John S; Ludwig A
    J Immunol; 2004 May; 172(10):6362-72. PubMed ID: 15128827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney.
    Schramme A; Abdel-Bakky MS; Gutwein P; Obermüller N; Baer PC; Hauser IA; Ludwig A; Gauer S; Schäfer L; Sobkowiak E; Altevogt P; Koziolek M; Kiss E; Gröne HJ; Tikkanen R; Goren I; Radeke H; Pfeilschifter J
    Kidney Int; 2008 Aug; 74(3):328-38. PubMed ID: 18480749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
    Gutwein P; Schramme A; Sinke N; Abdel-Bakky MS; Voss B; Obermüller N; Doberstein K; Koziolek M; Fritzsche F; Johannsen M; Jung K; Schaider H; Altevogt P; Ludwig A; Pfeilschifter J; Kristiansen G
    Eur J Cancer; 2009 Feb; 45(3):478-89. PubMed ID: 19070478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases.
    Schulte A; Schulz B; Andrzejewski MG; Hundhausen C; Mletzko S; Achilles J; Reiss K; Paliga K; Weber C; John SR; Ludwig A
    Biochem Biophys Res Commun; 2007 Jun; 358(1):233-40. PubMed ID: 17467666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.
    Hundhausen C; Schulte A; Schulz B; Andrzejewski MG; Schwarz N; von Hundelshausen P; Winter U; Paliga K; Reiss K; Saftig P; Weber C; Ludwig A
    J Immunol; 2007 Jun; 178(12):8064-72. PubMed ID: 17548644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
    Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
    Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
    Pruessmeyer J; Ludwig A
    Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
    Pupovac A; Foster CM; Sluyter R
    Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
    Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
    Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
    Ebsen H; Schröder A; Kabelitz D; Janssen O
    PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.
    Barlic J; Zhu W; Murphy PM
    J Immunol; 2009 Jun; 182(12):7928-36. PubMed ID: 19494317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
    Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
    Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
    Abu El-Asrar AM; Nawaz MI; Ahmad A; De Zutter A; Siddiquei MM; Blanter M; Allegaert E; Gikandi PW; De Hertogh G; Van Damme J; Opdenakker G; Struyf S
    Front Immunol; 2020; 11():601639. PubMed ID: 33552057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
    Gooden MJ; Wiersma VR; Boerma A; Leffers N; Boezen HM; ten Hoor KA; Hollema H; Walenkamp AM; Daemen T; Nijman HW; Bremer E
    Br J Cancer; 2014 Mar; 110(6):1535-44. PubMed ID: 24518602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.